lundi 10 avril 2017

Onco Actu du 10 avril 2017


3.3 Prévention - Vaccins

Short Answers to Hard Questions About HPV [NY Times]

4. Dépistage, diagnostic et pronostic

Advancing the Potential and Promise of Total-Body PET Imaging [NCI]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA Offers its Views on Medical Device Trials [RAPS]

4.11 Dép., diag. & prono. - Ovaire

Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene's Novel PARP Inhibitor, BGB-290 [Myriad]

PET imaging measures PARP-1 in ovarian cancer patients [FierceBiotech]

5. Traitements

Sperm Loaded with Drugs Could Target Gynecological Cancers [MIT Technology Review]

5.12 Immunothérapies

Trial Of Immune Drug In Breast Cancer Points To Need For Biomarkers [Forbes]

5.12.3 Immunothérapies-combinaisons

Immuno-oncology (IO) combination therapy- why the angst? [SugarCone Biotech]

Angst in the IO Combo field – part 2 (lessons from #AACR17) [SugarCone Biotech]

5.2 Pharma

Jazz Pharmaceuticals submits FDA application for leukaemia treatment [European Pharmaceutical Review]

Medivir posts lymphoma data, guns to get into phase 3 [FierceBiotech]

Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer [Roche]

5.3 Traitements - FDA, EMA, NICE...

Scott Gottlieb’s FDA Commissioner Confirmation Hearing: Remarkably Unremarkable [Health Affairs Blog]

Congress and FDA nominee heap love on ‘adaptive trials’ [Science]

FDA unease about faster drug approval [BMJ]

5.9 AACR

Delivering Cures Through Cancer Science - 2016 Annual Report [AACR]

Speaking of Cancer Research [The Scientist]

6.1 Observation

Lots of sleep tied to worse breast cancer survival odds [Reuters]

More prostate cancer patients get radiation when doctors own the equipment [Reuters]

6.10.1 Politiques (USA)

Biden: Trump’s cuts would set back cancer research by 15 years [The Cancer Letter]

6.9 Controverses

How Washington’s favorite cancer fighter helps himself [Politico]